Anti-inflammatory therapy for upper respiratory tract inflammatory diseases: NQO1 increases the expression of negative regulator of inflammation MyD88(s), inhibits pro-inflammatory mediators in lungs, and alleviates the common respiratory pathogen nontypeable Haemophilus influenzae (NTHi)-exacerbated asthma & chronic obstructive pulmonary disease via up-regulation of its target gene, 12/November/2015, 10.53 pm,

Natural product therapy for tuberculosis: Naringenin, a flavanone found in grapefruits, increases the expression of MKP-1, inhibits TLR2 signalling, secretion of Chemokine CXCL5, and recruitment of polymorphonuclear leukocytes (PMNs), decreases destructive pulmonary inflammation, promotes M. tuberculosis clearance and inhibits pulmonary tuberculosis via up-regulation of its target gene, 12/November/2016, 7.36 am
November 12, 2016
Natural product-based therapy for Regenerating the lost cardiomyocytes in Myocardial patients: Curcumin analog EF24 increases the expression of ERBB2/Her2 and promotes dedifferentiation of cardiomyocytes via down regulation of its target gene, 12/November/2015, 11.06 pm
November 12, 2016
Show all

Introduction: What they say: 

A study from the Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, 30303, USA shows that: “Resveratrol suppresses NTHi-induced inflammation via up-regulation of the negative regulator MyD88 short.” This study was published in the 28 September 2016 issue of the journal “Scientific reports” by Prof. Li JD, Andrews CS and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Anti-inflammatory therapy for upper respiratory tract inflammatory diseases: NQO1 increases the expression of negative regulator of inflammation MyD88(s), inhibits pro-inflammatory mediators in lungs, and alleviates the common respiratory pathogen nontypeable Haemophilus influenzae (NTHi)-exacerbated asthma & chronic obstructive pulmonary disease via up-regulation of its target gene


Significance:

Given that: (1) Pulmonary disease (PD) is a progressive degenerative disease of the lung, with debilitating consequences; (2) drugs that are currently used to treat inflammatory disease of the upper respiratory tract (URI) are ineffective, especially in aged patients; (3) molecular mechanisms involved in the development of URI inflammatory diseases is poorly understood; (4) Chronic obstructive inflammatory disease (COPD) is the third leading cause of death worldwide; (5) one-half billion people worldwide are affected by Asthma and COPD; (6) approx. 2. 5 lakhs of patients worldwide die of asthma every year; (7) microbes that cause these inflammatory diseases become resistant to conventional antibiotic therapy frequently; and (8) billions of dollars are being spent every year worldwide to treat these diseases, there is an urgent need to find: (i) a way to control abnormal levels of inflammatory mediators found in URI inflammatory disease patients; (ii) non-antibiotic therapeutics; (iii) a side-effect-free natural product-based drug; and (iv) a way to effectively treat and cure URI inflammatory disease.


What is known:  

Prof. Li’s research team has recently shown that Resveratrol, by increasing the negative regulator of inflammation MyD88(s), it suppresses NTH-1-exacerbated inflammation.


From Research Findings to Therapeutic opportunity: 

This study suggests, for the first time, that NQO1, by increasing the expression of its target gene, it may: (1) increase the expression of MKP/DUSP1; (2) decrease the phosphorylation and the activity of ERK1/2; (3) increase the expression of the negative regulator of inflammation MyD88-short. Thereby, it may inhibit: (1) respiratory pathogen NTHi-aggravated inflammation and its mediators such as IL-1β, IL-6, CCL-2 and GM-CSF; (2) lung inflammation; and (3) the progression of upper respiratory tract inflammatory diseases such as Asthma and Chronic obstructive inflammatory disease. Thus, pharmacological formulations encompassing “NQO1  activators” may be used to control inflammatory mediators in upper respiratory tract inflammatory diseases.


Idea Proposed/Formulated by: Dr L Boominathan Ph.D.

Web: http://genomediscovery.org org or http://newbioideas.com

To cite: Boominathan, L., Anti-inflammatory therapy for upper respiratory tract inflammatory diseases: NQO1 increases the expression of negative regulator of inflammation MyD88(s), inhibits pro-inflammatory mediators in lungs, and alleviates the common respiratory pathogen nontypeable Haemophilus influenzae (NTHi)-exacerbated asthma & chronic obstructive pulmonary disease via up-regulation of its target gene, 12/November/2015, 10.53 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/


Undisclosed information: How  NQO1 increases the expression of MyD88 (Short).

Amount: $200#

# Research cooperation

guaranteed-to-work1

Comments are closed.